STOCK TITAN

[Form 4] Bruker Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Bruker Corporation director and President & CEO Frank H. Laukien reported transactions on 08/15/2025. He received 48,431 shares of Common Stock via restricted stock units (RSUs) at no cash cost, bringing his reported direct beneficial ownership to 38,494,103 shares. The RSUs vest in four equal annual installments beginning one year after the grant.

He also was granted a stock option to purchase 137,339 shares with a $36.872 exercise price; the option vests in four equal annual installments starting 08/15/2026 and expires 08/15/2030. The filing lists several indirect holdings: 1,055,639 shares by a former spouse, 337,087 by a son, 336,607 by a daughter, and additional custodial holdings described in the form.

Il direttore nonché Presidente e Amministratore Delegato di Bruker Corporation, Frank H. Laukien, ha segnalato operazioni il 15/08/2025. Ha ricevuto 48.431 azioni ordinarie tramite unità azionarie vincolate (RSU) senza alcun esborso in contanti, portando la sua partecipazione beneficiaria diretta dichiarata a 38.494.103 azioni. Le RSU maturano in quattro quote annuali uguali a partire da un anno dopo la concessione.

Gli è stata inoltre concessa un'opzione su azioni per acquistare 137.339 azioni a un prezzo di esercizio di 36,872 $; l'opzione matura in quattro quote annuali uguali a partire dal 15/08/2026 e scade il 15/08/2030. La comunicazione elenca diverse partecipazioni indirette: 1.055.639 azioni da parte di un'ex coniuge, 337.087 da parte di un figlio, 336.607 da parte di una figlia e ulteriori detenute in custodia descritte nel modulo.

El director y Presidente y CEO de Bruker Corporation, Frank H. Laukien, informó transacciones el 15/08/2025. Recibió 48.431 acciones ordinarias mediante unidades restringidas de acciones (RSU) sin costo en efectivo, elevando su propiedad beneficiaria directa reportada a 38.494.103 acciones. Las RSU devengan en cuatro cuotas anuales iguales a partir de un año después de la concesión.

También se le concedió una opción sobre acciones para comprar 137.339 acciones con un precio de ejercicio de 36,872 $; la opción devenga en cuatro cuotas anuales iguales a partir del 15/08/2026 y vence el 15/08/2030. La presentación enumera varias participaciones indirectas: 1.055.639 acciones por parte de una exesposa, 337.087 por un hijo, 336.607 por una hija y otras posiciones en custodia descritas en el formulario.

Bruker Corporation 이사 겸 사장 겸 CEO인 Frank H. Laukien이 2025년 8월 15일 거래를 신고했습니다. 그는 현금 비용 없이 제한부주식단위(RSU)로 48,431주의 보통주를 받았으며, 그로써 보고된 직접 실소유 주식 수는 38,494,103주가 되었습니다. RSU는 부여일로부터 1년 후에 시작해 4년간 매년 동일한 비율로 베스팅됩니다.

또한 그는 행사 가격이 $36.872인 137,339주를 매수할 수 있는 스톡옵션을 부여받았으며; 이 옵션은 2026-08-15부터 4년간 매년 동일 비율로 베스팅되고 2030-08-15에 만료됩니다. 신고서에는 여러 간접 보유가 기재되어 있습니다: 전 배우자가 보유한 1,055,639주, 아들이 보유한 337,087주, 딸이 보유한 336,607주 및 양육자 명의로 된 추가 보유분이 양식에 설명되어 있습니다.

Le directeur et Président-directeur général de Bruker Corporation, Frank H. Laukien, a déclaré des transactions le 15/08/2025. Il a reçu 48 431 actions ordinaires via des unités d'actions restreintes (RSU) sans contrepartie en espèces, portant sa propriété bénéficiaire directe déclarée à 38 494 103 actions. Les RSU acquièrent des droits en quatre versements annuels égaux à partir d'un an après l'attribution.

Il s'est également vu accorder une option d'achat portant sur 137 339 actions à un prix d'exercice de 36,872 $ ; l'option acquiert des droits en quatre versements annuels égaux à partir du 15/08/2026 et expire le 15/08/2030. Le dépôt liste plusieurs avoirs indirects : 1 055 639 actions par une ex-épouse, 337 087 par un fils, 336 607 par une fille et d'autres avoirs en garde décrits dans le formulaire.

Der Direktor sowie Präsident und CEO von Bruker Corporation, Frank H. Laukien, meldete Transaktionen am 15.08.2025. Er erhielt 48.431 Stammaktien durch Restricted Stock Units (RSUs) ohne Baraufwand, womit sein gemeldetes direktes wirtschaftliches Eigentum auf 38.494.103 Aktien anstieg. Die RSUs werden in vier gleichen jährlichen Raten beginnend ein Jahr nach Gewährung unverfallbar.

Ihm wurde außerdem eine Aktienoption zum Kauf von 137.339 Aktien zu einem Ausübungspreis von 36,872 $ gewährt; die Option wird in vier gleichen jährlichen Raten ab dem 15.08.2026 unverfallbar und verfällt am 15.08.2030. Die Meldung führt mehrere indirekte Beteiligungen auf: 1.055.639 Aktien durch eine Ex-Ehefrau, 337.087 durch einen Sohn, 336.607 durch eine Tochter sowie weitere treuhänderische Bestände, die im Formular beschrieben sind.

Positive
  • Significant direct ownership reported: 38,494,103 shares, indicating substantial insider stake
  • New equity grants (48,431 RSUs and 137,339 options) align executive incentives with long-term shareholder value
  • Standard four-year vesting for both RSUs and options supports retention and long-term alignment
Negative
  • No reported negative items such as share disposals, sales, or material deviations from standard compensation shown in this filing

Insights

TL;DR: CEO received RSUs and options totaling meaningful equity, aligning management compensation with shareholder value.

The Form 4 documents a grant of 48,431 RSUs and a 137,339-share option at a $36.872 strike. RSU and option grants that vest over four years create multi-year retention incentives and potential upside exposure to future share-price appreciation. The CEO's large direct holding of 38.49 million shares suggests substantial existing alignment with shareholders. These are routine compensation-related insider transactions; no sales or disposals were reported.

TL;DR: Grants follow standard multi-year vesting schedules, supporting retention without immediate dilution from exercised options.

The filing shows conventional four-year vesting for both RSUs and options, which is consistent with long-term incentive design. The option strike of $36.872 and the RSU zero purchase price indicate compensation rather than market purchases. Indirect holdings disclosed for family and custodial accounts are properly reported, demonstrating compliance with Section 16 reporting obligations. No amendments or unusual transaction codes are present.

Il direttore nonché Presidente e Amministratore Delegato di Bruker Corporation, Frank H. Laukien, ha segnalato operazioni il 15/08/2025. Ha ricevuto 48.431 azioni ordinarie tramite unità azionarie vincolate (RSU) senza alcun esborso in contanti, portando la sua partecipazione beneficiaria diretta dichiarata a 38.494.103 azioni. Le RSU maturano in quattro quote annuali uguali a partire da un anno dopo la concessione.

Gli è stata inoltre concessa un'opzione su azioni per acquistare 137.339 azioni a un prezzo di esercizio di 36,872 $; l'opzione matura in quattro quote annuali uguali a partire dal 15/08/2026 e scade il 15/08/2030. La comunicazione elenca diverse partecipazioni indirette: 1.055.639 azioni da parte di un'ex coniuge, 337.087 da parte di un figlio, 336.607 da parte di una figlia e ulteriori detenute in custodia descritte nel modulo.

El director y Presidente y CEO de Bruker Corporation, Frank H. Laukien, informó transacciones el 15/08/2025. Recibió 48.431 acciones ordinarias mediante unidades restringidas de acciones (RSU) sin costo en efectivo, elevando su propiedad beneficiaria directa reportada a 38.494.103 acciones. Las RSU devengan en cuatro cuotas anuales iguales a partir de un año después de la concesión.

También se le concedió una opción sobre acciones para comprar 137.339 acciones con un precio de ejercicio de 36,872 $; la opción devenga en cuatro cuotas anuales iguales a partir del 15/08/2026 y vence el 15/08/2030. La presentación enumera varias participaciones indirectas: 1.055.639 acciones por parte de una exesposa, 337.087 por un hijo, 336.607 por una hija y otras posiciones en custodia descritas en el formulario.

Bruker Corporation 이사 겸 사장 겸 CEO인 Frank H. Laukien이 2025년 8월 15일 거래를 신고했습니다. 그는 현금 비용 없이 제한부주식단위(RSU)로 48,431주의 보통주를 받았으며, 그로써 보고된 직접 실소유 주식 수는 38,494,103주가 되었습니다. RSU는 부여일로부터 1년 후에 시작해 4년간 매년 동일한 비율로 베스팅됩니다.

또한 그는 행사 가격이 $36.872인 137,339주를 매수할 수 있는 스톡옵션을 부여받았으며; 이 옵션은 2026-08-15부터 4년간 매년 동일 비율로 베스팅되고 2030-08-15에 만료됩니다. 신고서에는 여러 간접 보유가 기재되어 있습니다: 전 배우자가 보유한 1,055,639주, 아들이 보유한 337,087주, 딸이 보유한 336,607주 및 양육자 명의로 된 추가 보유분이 양식에 설명되어 있습니다.

Le directeur et Président-directeur général de Bruker Corporation, Frank H. Laukien, a déclaré des transactions le 15/08/2025. Il a reçu 48 431 actions ordinaires via des unités d'actions restreintes (RSU) sans contrepartie en espèces, portant sa propriété bénéficiaire directe déclarée à 38 494 103 actions. Les RSU acquièrent des droits en quatre versements annuels égaux à partir d'un an après l'attribution.

Il s'est également vu accorder une option d'achat portant sur 137 339 actions à un prix d'exercice de 36,872 $ ; l'option acquiert des droits en quatre versements annuels égaux à partir du 15/08/2026 et expire le 15/08/2030. Le dépôt liste plusieurs avoirs indirects : 1 055 639 actions par une ex-épouse, 337 087 par un fils, 336 607 par une fille et d'autres avoirs en garde décrits dans le formulaire.

Der Direktor sowie Präsident und CEO von Bruker Corporation, Frank H. Laukien, meldete Transaktionen am 15.08.2025. Er erhielt 48.431 Stammaktien durch Restricted Stock Units (RSUs) ohne Baraufwand, womit sein gemeldetes direktes wirtschaftliches Eigentum auf 38.494.103 Aktien anstieg. Die RSUs werden in vier gleichen jährlichen Raten beginnend ein Jahr nach Gewährung unverfallbar.

Ihm wurde außerdem eine Aktienoption zum Kauf von 137.339 Aktien zu einem Ausübungspreis von 36,872 $ gewährt; die Option wird in vier gleichen jährlichen Raten ab dem 15.08.2026 unverfallbar und verfällt am 15.08.2030. Die Meldung führt mehrere indirekte Beteiligungen auf: 1.055.639 Aktien durch eine Ex-Ehefrau, 337.087 durch einen Sohn, 336.607 durch eine Tochter sowie weitere treuhänderische Bestände, die im Formular beschrieben sind.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAUKIEN FRANK H

(Last) (First) (Middle)
C/O BRUKER CORPORATION
40 MANNING ROAD

(Street)
BILLERICA MA 01821

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BRUKER CORP [ BRKR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT & CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A 48,431(1) A $0 38,494,103 D
Common Stock 1,055,639 I By Former Spouse
Common Stock 337,087 I By Son
Common Stock 336,607 I By Daughter
Common Stock 201,702 I As UTMA Custodian for Son
Common Stock 71,728 I As UTMA Custodian for Son
Common Stock 1,043 I By Former Spouse
Common Stock 272 I By Son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase) $36.872 08/15/2025 A 137,339 08/15/2026(2) 08/15/2030 Common Stock 137,339 $0 137,339 D
Explanation of Responses:
1. The Restricted Stock Units granted to the Reporting Person on August 15, 2025 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date.
2. The Stock Options granted to the Reporting Person on August 15, 2025 (the "Original Grant Date") vest in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date.
/s/ Michael A Simone, Attorney-in-Fact 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bruker (BRKR) insider Frank H. Laukien acquire on 08/15/2025?

He was granted 48,431 restricted stock units (RSUs) and a stock option covering 137,339 shares with a $36.872 exercise price.

When do the RSUs and options vest for Frank H. Laukien?

Both the RSUs and the options vest in four equal annual installments beginning one year after the original grant date (first vesting on 08/15/2026 for options).

How many Bruker shares does Frank H. Laukien beneficially own directly after the transaction?

The filing reports 38,494,103 shares beneficially owned directly following the reported transaction.

Are there indirect holdings disclosed for Frank H. Laukien in this Form 4?

Yes. The filing lists indirect holdings including 1,055,639 shares by a former spouse, 337,087 by a son, 336,607 by a daughter, and various custodial holdings.

What is the expiration date of the stock option granted to Laukien?

The stock option expires on 08/15/2030.
Bruker Corp

NASDAQ:BRKR

BRKR Rankings

BRKR Latest News

BRKR Latest SEC Filings

BRKR Stock Data

5.19B
103.27M
31.91%
83.8%
6.15%
Medical Devices
Laboratory Analytical Instruments
Link
United States
BILLERICA